Malignant Peripheral Nerve Sheath Tumor of the C2 Nerve Root: Case Report

Joshua D. Burks1 Robert G. Briggs1 Chad A. Glenn1 John C. Greenert2 Cordell M. Baker1 Keren Bartal3 Greg A. Krempl3 Michael E. Sughrue1

1Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
2Department of Neurology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
3Department of Otorhinolaryngology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

J Neurol Surg Rep 2017;78:e68–e70.

Address for correspondence Michael E. Sughrue, MD, Department of Neurosurgery, University of Oklahoma Health Sciences Center, 1000 N. Lincoln Blvd., Suite 4000, Oklahoma City, OK 73104, United States (e-mail: michael-sughrue@ouhsc.edu).

Introduction

Malignant peripheral nerve sheath tumor (MPNST) is an uncommon tumor that can occur virtually anywhere in the body.1 These tumors proliferate rapidly and behave aggressively. Here we present the unusual case of a MPNST growing from the C2 nerve root in an otherwise healthy young man.

Case Report

History and Examination

A 36-year-old man presented with hoarseness and right-sided tongue deviation following several months of worsening headaches. On magnetic resonance imaging (MRI), he was found to have a large, contrast-enhancing lesion in the right carotid space displacing the internal jugular vein laterally and the common carotid anteriorly, as shown in –Fig. 1. Imaging also demonstrated extension into the neural foramina at C1–C2 and the hypoglossal canal. It was determined that the patient’s symptoms were likely due to cranial nerve involvement by the mass. Given the rapid onset of symptoms, the patient’s deficits were expected to worsen with time as the tumor continued to proliferate. Consequently, the patient elected to undergo surgical resection.

Operation and Postoperative Course

The tumor was resected through a combined far-lateral, suboccipital neck dissection to allow for good exposure of the ventrolateral brainstem and upper spinal cord. Incision lines are shown in –Fig. 2. The sternocleidomastoid and spinal accessory nerve were retracted to expose the great vessels, as shown in –Figs. 3A and 3B. The tumor was then dissected free from the carotid sheath and vagus nerve. The lateral suboccipital space was exposed to the C2 spinal nerve’s exit from the thecal sac, where this portion of the tumor was removed en bloc. The tumor was then dissected off the vertebral artery as in –Fig. 3C and was also dissected where it involved cranial nerves X and XII at the jugular foramen. Gross total resection was achieved around these structures with adequate margins, as shown in –Fig. 3D. Histopathology revealed components of MPNST. The patient was discharged 5 days postoperatively with partial posterior scalp numbness and an otherwise normal neurologic examination. He was subsequently treated with radiation therapy, and at his 6-month follow-up, he had no evidence of recurrence.

Keywords

► malignant peripheral nerve sheath tumor
► skull base
► cervical nerve root

Abstract

Here we present the case of a 36-year-old man who was found to have a symptomatic malignant neural sheath tumor growing from the C2 nerve root following a period of progressively worsening headaches. The patient was successfully treated with surgical resection resulting in resolution of cranial nerve deficits. Though uncommon, malignant peripheral nerve sheath tumor must be considered in the differential diagnosis of tumors involving the cervical nerve roots and carotid space.
**Discussion**

MPNST is a rare entity defined as a malignant tumor arising from a peripheral nerve or having nerve sheath differentiation. These tumors are most often found in the extremities and trunk, though approximately 20% occur in the head and neck. Making the diagnosis can be difficult, as MPNST histopathology has shown marked variability with possible divergent differentiation (e.g., rhabdomyosarcomatous differentiation consistent with our patient’s tumor). Furthermore, MRI cannot distinguish between malignant and benign nerve sheath tumors.

The nature of MPNST is highly aggressive and carries a poor prognosis. Current 5-year survival rates are reported from 44 to 60% for patients with any MPNST. The mainstay of treatment is maximal surgical resection with adjuvant radiotherapy for local tumor control. Some have shown that surgery and radiotherapy do not confer any survival benefit, but do delay time to local recurrence. Others have shown that lack of radiation predicts decreased disease-specific survival. Typically, chemotherapy is not used to treat these tumors, although some have questioned this view with more recent reports detailing the improved survival benefit in patients with MPNST treated with doxorubicin and ifosfamide. Given their limited sample size, however, additional research into the role of chemotherapy in treating MPNST is necessary. Fitting with standard practices, our patient received adjuvant radiation following surgery.

To our knowledge, this case is the first report of MPNST occurring in the upper cervical nerve roots and hypoglossal nerve. Previous reports of MPNST occurring within the cervical spine and brainstem include one case of a 23-year-old woman who was diagnosed 17 months following resection of a schwannoma. The schwannoma was initially resected from the C7–T1 cord level, followed by posterior fusion of C3–T3 and sacrifice of the C8 nerve root. The tumor later recurred as low-grade MPNST at the C3–T3 cord level. In another report, a 30-year-old woman was found to have MPNST involving the sixth cranial nerve. The tumor was resected through an extended left retrosigmoid craniotomy to access the anterior cerebellopontine angle and brainstem. At 1-year follow-up, the patient was neurologically intact with a small amount of residual tumor.

In addition to sporadic MPNST, malignant nerve sheath tumors classically occur as a result of malignant transformation of an existing plexiform neurofibroma in the setting of neurofibromatosis type 1 (NF-1). Patients with NF-1 carry a 10% lifetime risk of such a transformation; however, 36% of MPNST cases are thought to occur in patients with NF-1 without a previous neurofibroma diagnosis. Given that our patient did not have additional signs or symptoms of NF-1, including other neurocutaneous disease or a family history of NF-1, we felt his malignancy was likely sporadic.

Though uncommon, MPNST must be considered in the differential diagnosis of tumors involving the cervical nerve
roots and the carotid space even without a history of neurofibromatosis.

Disclosure
The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this report.

Funding
None.

Acknowledgments
None.

References